Cardiol Therapeutics Inc Class A has seen notable price movement this week, reflecting positive developments in its clinical trials and financing efforts.
Cardiol Therapeutics Inc Class A (CRDL.TO) has gained traction this week, with a 12.96% increase in stock price. The company recently announced significant operational updates and financing that may have contributed to this upward momentum. Let’s explore the recent developments and the technical picture for Cardiol Therapeutics.
Advertisement
Cardiol Therapeutics Inc Class A
CRDL.TO
CRDL.TO
Cardiol Therapeutics Inc Class A
WealthAwesomeMarket cap
$356.31M
52W high
$3.15
52W low
$1.23
1W change
+12.96%
Beta
0.61
Analyst Price Targets
Based on analyst covering CRDL
Wall Street analysts forecast CRDL stock price to rise 96.7% over the next 12 months.
Consensus
BullishBased on avg. target vs last close (formal rating unavailable for Canadian listings)
Avg. Target
C$6.00
+96.7% Upside
Current Price
C$3.05
Last close
Analyst ratings and price targets are updated periodically. Not financial advice.
Wealth Awesome Price Forecast
WA ModelStatistical 90-day price range based on CRDL's historical volatility
30-Day Vol
70.5%
Annualized
90-Day Vol
56.7%
Annualized
Trend (90d)
+50.0%
Annualized drift
90d Mean
C$3.65
Expected price
| Horizon | Expected | 68% Range (1σ) |
|---|---|---|
| 30 trading days | C$3.24 | C$2.54 – C$4.13 |
| 60 trading days | C$3.44 | C$2.44 – C$4.85 |
| 90 trading days | C$3.65 | C$2.39 – C$5.56 |
Methodology: Range is calculated using 30-day realized volatility via geometric Brownian motion (log-normal model). 68% band = ±1σ, 95% band = ±2σ. This is a statistical model, not a prediction. Past volatility does not guarantee future results. Not financial advice.
Advertisement
Investor takeaway: Investors may find Cardiol Therapeutics' recent advancements in clinical trials and its strengthened financial position encouraging. However, the company's current lack of profitability and negative return on equity should be considered when evaluating its long-term prospects.
Cardiol Therapeutics Stock Up 12.96% This Week
The stock has risen significantly over the past month, reflecting a 60.53% increase, underscoring growing investor interest amid clinical advancements.
Bull case
Cardiol Therapeutics recently completed a private placement offering, raising US$11.4 million. This funding extends the company’s cash runway into Q3 2027, allowing it to continue its clinical trials and meet operational milestones.
Bear case
Despite the recent gains, Cardiol Therapeutics is still operating at a loss, with a negative profit margin and return on equity. Investors should remain cautious about the company's long-term sustainability given its current financial metrics.
Recent Price Action
Advertisement
Cardiol Therapeutics Inc Class A has seen a price increase of 2.35% on the last trading day, bringing its closing price to C$3.02. Over the past week, the stock has gained 12.96%, and its performance over the last month has been particularly strong, with a 60.53% rise. Year-to-date, the stock has appreciated by an impressive 124.26%, indicating a robust upward trend.
Catalysts Behind the Move
Recent headlines indicate that Cardiol Therapeutics has made significant strides in its operations. The company announced the initiation of the Phase III MAVERIC trial for recurrent pericarditis and reported positive Phase II ARCHER data. Furthermore, the completion of a private placement offering raised US$11.4 million, extending its cash runway into Q3 2027 and fully funding the MAVERIC Phase III trial. These developments have likely contributed to the stock's recent performance.
Technical Picture
From a technical standpoint, Cardiol Therapeutics is trading well above its 50-day moving average of C$2.02 (up 49.8% from the current price) and its 200-day moving average of C$1.67 (up 81.3%). The stock has a 52-week range of C$1.23 to C$3.15, indicating that it is currently trading at 93% of its range. With a beta of 0.61, the stock exhibits lower volatility compared to the broader market, making it potentially less risky for investors.
Best next step
Keep exploring this topic
If you want to go deeper, these are the most useful follow-up pages and tools for this topic.
Broker comparison
Best trading platforms in Canada
Compare $0-commission brokers before you act on a ticker story.
Safe cash
Best GIC rates in Canada
If the story makes you want to de-risk, compare guaranteed rates next.
HISA roundup
Best high-interest savings accounts
Keep dry powder in a no-fee savings account instead of chequing.
TFSA room
Check TFSA contribution room
Shelter the next contribution before you buy.
Advertisement
Wealth Awesome
Timely coverage of Canadian stocks, earnings, dividends, and market movers for DIY investors. Stories are checked against exchange data and public filings.
View Full Profile →✅ Reviewed by Certified Financial Professionals
This content has been reviewed by CFA® charterholders and Certified Financial Planners (CFP®) with over a decade of experience in Canadian financial markets. All information is fact-checked against official Canadian sources and regulations.
Why these credentials matter: CFA® charterholders complete 900+ hours of rigorous study in investment analysis and ethics. CFP® professionals are held to the highest standards of financial planning competency and fiduciary duty in Canada.
⚠️ Professional Disclaimer
This content is for educational purposes only and should not be considered personalized financial advice. While our team brings professional expertise, individual circumstances vary. For personalized guidance, consult with a qualified financial advisor, tax professional, or mortgage specialist.
